HCPLive
San Antonio Breast Cancer Symposium 2009
The 2009 San Antonio Breast Cancer Symposium (SABCS) is presented by the CTRC, AACR, and the Baylor College of Medicine. The driving force behind this collaboration is the shared mission of the organizations to advance progress against breast cancer. By combining their respective strengths, the San Antonio Breast Cancer Symposium encompasses the full spectrum of breast cancer research and facilitates the rapid transition of new knowledge into improved care for breast cancer patients.
Day 4
For patients with early breast cancer, peripheral neurotoxicity is an unfortunate side effect of treatment with taxanes, but there may be a silver lining.
Anthracycline chemotherapy plus trastuzumab outperformed anthracycline alone, and performed similarly to a non-anthracycline regimen in breast cancer patients.
Many patients who chose mastectomy were not at increased breast-cancer risk and may have done so based on a failed attempt at breast-conservation surgery.
In the BIG 1-98 trial, high-risk patients did best with 5 years of letrozole and low-risk patients did similarly well with any of the trial%u2019s regimens.
A study recommends use of trastuzumab concurrently with the taxane portion of chemotherapy for breast cancer patients.
Day 3
Adding bevacizumab to chemotherapy improved survival compared with chemotherapy alone in breast cancer patients.
Sorafenib showed promise when combined with chemotherapy for locally advanced or metastatic breast cancer.
Lung cancer deaths are significantly less common in breast cancer patients who are treated with anti-estrogens.
Updated results confirm that addition of bevacizumab to docetaxel as first-line breast cancer treatment improves survival and response rates.
About 10 months of neoadjuvant letrozole is optimal for breast-conserving surgery in patients with early breast cancer.
Day 2
Clinical trials suggest that lapatinib can overcome resistance to trastuzumab in women with metastatic HER2-positive breast cancer.
Letrozole treatment over 5 years was still associated with significantly better overall survival than 5 years with tamoxifen.
Doubling the dose of fulvestrant increases the time to disease progression in the treatment of postmenopausal women with breast cancer.
A study reveals a beneficial effect of tamoxifen on breast cancer recurrences at 10 and 15 years of follow-up in women with ductal carcinoma in situ (DCIS).
The multi-targeted kinase inhibitor sorafenib, approved to treat kidney and liver cancer, may also benefit patients with metastatic breast cancer.
Day 1
Which is better: Tamoxifen upfront followed by an aromatase inhibitor (AI) for 5 years, or an AI for 5 years. Final results failed to resolve this issue.
Postmenopausal women with breast cancer who use exemestane after taking tamoxifen have superior outcomes than those who stay on tamoxifen for 5 years.
Consumption of just a half drink per day, or two to three per week, raised the risk of recurrence of breast cancer in women by 39%.
The use of oral bisphosphonates may protect against the development of invasive breast cancer, according to a new analysis by the Women's Health Initiative.
The RANK ligand inhibitor denosumab was better than the standard-of-care bisphosphonate, zoledronic acid in breast cancer patients with bone metastases.
Sign up for HCPLive eNewsletters
*Firstname:
*Lastname:
*Email:
*Practice Type:

Intellisphere, LLC
666 Plainsboro Road
Building 300
Plainsboro, NJ 08536
P: 609-716-7777
F: 609-716-4747

Copyright HCPLive 2006-2011
Intellisphere, LLC. All Rights Reserved.
 




Become a Member